Bortezomib-d8
€ Preis anfragen
Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].
- Purity: 98.0
- Formula: C19H17D8BN4O4
- Solubility: 10 mM in DMSO
- SMILES: OB([C@H](CC(C)C)NC(C(NC(C1=NC=CN=C1)=O)([2H])C([2H])([2H])C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])=O)O
- Molecular Weight: 392.29
-20°C (Powder, stored under nitrogen)
For research use only. Not to be used for human or animal treatment or consumption.
Ausgewählte Produkte
